NGNE Neurogene Inc

Price (delayed)

$23.1

Market cap

$478.19M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.1

Enterprise value

$406.46M

?
Relative Growth: Rel. Growth: 4
Relative Strength: Rel. Strength: 39
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Neoleukin is a biopharmaceutical company that has historically created next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin developed sophisticated computational methods to design ...

Highlights
NGNE's quick ratio has soared by 89% from the previous quarter and by 10% YoY
NGNE's equity has soared by 63% QoQ and by 34% YoY
Neurogene's net income has decreased by 40% YoY and by 7% QoQ
NGNE's EPS is down by 24% YoY

Key stats

What are the main financial stats of NGNE

NGNE stock price

How has the Neurogene stock price performed over time
Intraday
-0.86%
1 week
-8.62%
1 month
-0.65%
1 year
2.85%
YTD
12.14%
QTD
-16.97%

Financial performance

How have Neurogene's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$129.92M
Net income
-$119.18M
Gross margin
N/A
Net margin
N/A
Neurogene's net income has decreased by 40% YoY and by 7% QoQ
NGNE's operating income is down by 34% year-on-year and by 7% since the previous quarter

Price vs fundamentals

How does NGNE's price correlate with its fundamentals

Growth

What is Neurogene's growth rate over time

Valuation

What is Neurogene stock price valuation
P/E
N/A
P/B
1.3
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NGNE's EPS is down by 24% YoY
NGNE's equity has soared by 63% QoQ and by 34% YoY
The stock's price to book (P/B) is 18% less than its last 4 quarters average of 1.6

Efficiency

How efficient is Neurogene business performance
The company's return on invested capital has shrunk by 74% YoY but it rose by 4.3% QoQ
The ROE has contracted by 49% YoY
NGNE's return on assets is down by 48% year-on-year

Dividends

What is NGNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NGNE.

Financial health

How did Neurogene financials performed over time
NGNE's quick ratio has soared by 89% from the previous quarter and by 10% YoY
Neurogene's current ratio has surged by 88% QoQ and by 9% YoY
NGNE's debt is 98% smaller than its equity
NGNE's equity has soared by 63% QoQ and by 34% YoY
Neurogene's debt to equity has plunged by 50% from the previous quarter and by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.